CareDx Announces New HLA Typing Service Offering for Research Purposes
CareDx, Inc. (CDNA) has launched a next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden, aimed at supporting research in vaccine and drug development.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CareDx, Inc. (CDNA) has launched a next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden, aimed at supporting research in vaccine and drug development. This HLA typing service, powered by AlloSeq Tx17, offers superior gene content and efficient testing capabilities. The service has already been engaged by a top global pharmaceutical company. CareDx is focusing on expanding its global presence and enhancing support for drug development research, enhancing patient care worldwide.
Positive
- Launch of a next generation sequencing (NGS) HLA typing service lab in Stockholm, expanding global operations.
- Engagement with a top 10 global pharmaceutical company for HLA typing services.
- AlloSeq Tx17 offers over 50% more gene content than competitors, enhancing research capabilities.
Negative
- None.
Details
News Market Reaction – CDNA
The recorded move for CDNA in the trading session of this news was +1.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial projects underway for global pharmaceutical company
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that they have launched a fully-functional next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies.
The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time. AlloSeq Tx17 provides over
CareDx’s HLA typing service in Stockholm has been engaged by one of the top 10 global pharmaceutical companies in the world, providing initial testing results in the first quarter of 2021.
“This is an exciting time for CareDx – we are not only expanding our capabilities but also investing in our global team to provide a first ever CareDx testing service outside the United States,” said Alexander Johnson, SVP, Products, Cell Therapy and Business Development, CareDx. “This expansion allows us to partner with those at the forefront of drug development research and support improved care for even more patients around the world.”
For more information on HLA typing services in Europe, please contact hlatypingservice@caredx.com
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
CONTACTS:
CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
Greg Chodaczek
347-610-7010
investor@caredx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.